First make the distinction between and actual lawsuit and advertisement. There is very little substance to the claims. The efficacy was proven clinically by Intrinsa and Phase II results. The market potential was covered by the the size of the target audience post menopausal women with HSDD and the Independent surveys that were conducted. Combine this with the fact that the insiders were still buying shares. shoots holes in any claim. Likewise if the product gets approval Those who are suing shot themselves in the foot by selling prematurely.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.